20 results about "Retinitis" patented technology

Provided herein is a method of treating a condition associated with nuclear speckle sphericity in a patient, including administering to the patient an amount of a composition including a nuclear speckle rejuvenator effective to reduce nuclear speckle sphericity in the patient.

To provide Akt3 modulators and compounds and pharmaceutical compositions for treating diseases by modulation of Akt3 signaling.SOLUTION: A compound of Formula Ib or Ic, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising said compound for treating a disease in a subject in need thereof, A pharmaceutical composition wherein the treatment comprises administering to a subject an effective amount of the compound; optionally wherein the disease is selected from the group consisting of neurodegenerative diseases, cachexia, eating disorders, obesity, complications of obesity, inflammatory diseases, virally-induced inflammatory reactions, Gulf War Syndrome, tuberous sclerosis, retinitis pigmentosa, graft rejection, cancer, autoimmune diseases, ischemic tissue injury, traumatic tissue injury and combinations thereof.SELECTED DRAWING: Figure 6

CRISPR / Cas-related compositions and methods for treatment of Usher Syndrome and / or Retinitis Pigmentosa are disclosed herein.

The application provides application of thrombospondin 1 in preparation of a drug for preventing and / or treating retinal injury, and belongs to the technical field of eye disease drugs. The application verifies the anti-inflammatory effect of thrombospondin 1 (THBS-1) in experimental blue light induced retinal inflammation by means of in vitro cell experiments and in vivo animal experiments, and verifies the role of thrombospondin 1 in inhibiting pathological neovascularization and the protective effect on retinal injury. Therefore, the application provides application of thrombospondin 1 in preparation of a drug for preventing and / or treating age-related macular degeneration.

A microorganism containing Bacteroides fragilis genes is used as an active ingredient in the preparation of pharmaceuticals, medical devices, or food for treating optic nerve damage. This delivers Bacteroides fragilis (or its functional components) into the gastrointestinal tract, which helps maintain the number of retinal ganglion cells and the thickness of the retinal nerve fiber layer, inhibits the activation of retinal microglia, inhibits the activation of retinal inflammatory pathways and the expression of inflammatory mediators, thereby protecting visual function.

The microorganism contains the bacteroides fragilis gene, and the bacteroides fragilis gene is used as an active ingredient to be applied to preparation of medicine or food for treating optic nerve damage, the bacteroides fragilis (or functional components thereof) is delivered to gastrointestinal tracts, the number of retinal ganglion cells and the thickness of a retinal nerve fiber layer can be maintained, activation of retinal microglia cells is inhibited, and optic nerve damage is inhibited. Retina inflammation pathway activation and inflammatory mediator expression are inhibited, so that the visual function is protected.

Methods for facilitating the genesis of photoreceptor rods in a subject by administering a therapeutically effective amount of a therapeutic agent are provided. Other methods are provided for treating retinitis pigmentosa by administering a therapeutically effective dose of therapeutic agents. Methods for producing an in vitro population of progenitor cells and photoreceptor rods generated therefrom are also provided.

Microparticulate (MP) formulations formed from one or more poly(hydroxyacid) polymers having a molecular weight ranging from 5kD to 60kD, and one or more active agents are injected into the eye of a subject to address eye disorders. The MP formulations assure high drug loading and extended delivery of the active agent of six to twelve months. The active agents may include peroxisome proliferator-activated receptor alpha (PPARα) signaling agonists such as PPARα agonist A190 (IUPAC name 3-((4-((4-fluorobenzyl)oxy)- 3- methylbenzyl)amino)benzoic acid). The formulations have therapeutic and protective effects against retinal degeneration diseases such as age-related macular degeneration (AMD), but may also be used for treating or relieving the symptoms of retinal inflammation, retinal neovascularization, retinal vascular leakage, retinopathy of prematurity (ROP), diabetic retinopathy (DR), and diabetic macular edema (DME).

Described herein are certain methods of treating a subject with retinitis pigmentosa, the method comprising administering to the subject a therapeutically effective dose of a rhodopsin corrector molecule thereby treating the retinitis pigmentosa.

The present invention is directed vectors comprising a FCBR1-F0.4 promotor or an IRBP-GRK1 promotor and a nucleic acid sequence encoding a ciliary protein, or fragment or variant thereof. In particular, the invention relates to a method of treatment and prevention of retinal ciliopathies, such as retinitis pigmentosa 28.

The present disclosure relates to the technical field of biomedicine, and in particular to use of miRNA or modified miRNA in treating fundus oculi diseases. The miRNA or modified miRNA has biological activity, can be absorbed by cells in vitro or retina cells in vivo, and quickly plays a biological role. Through a topical administration mode, the miRNA or the modified miRNA can inhibit pathological neovascularization, promote recovery of a non-perfusion region, reduce expression of retinal inflammatory factors, relieve retinal fibrosis, and promote nerve injury repair. The method has very good application and research values in the field of biomedicine.

The present invention relates to an ulva australis extract with antioxidant activity and cell proliferation activity for use as a drug to prevent and / or treat neurodegenerative diseases of the retina, especially those associated with oxidative stress or loss of photoreceptors, such as age-related macular degeneration, glaucoma, inherited retinal dystrophies, diabetic retinopathy and retinitis pigmentosa.

Applicant provides a method for treating or preventing a TMEM216-related disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a gene that supports or restores functional TMEM216 in the patient, such as for example retinitis pigmentosa (RP) or Joubert syndrome 2. The subject to be treated can be identified as harboring a mutation in the 5'UTR of GRCh38: chrll:g.61392563G. Also provided are vectors comprising the gene that supports or restores functional TMEM 216 in the subject. Diagnostic tests to identify these subjects also are provided herein.

The present application relates to methods of treating ocular diseases. In particular, the present application provides the use of a combination therapy of administering a thymidylate synthetase inhibitor and a vascular endothelial growth factor inhibitor and a monotherapy of administering capecitabine in ocular diseases. The diseases have one or more of the following characteristics: ocular vascular leakage, ocular vascular pathology, retinal fibrosis, scarring, and retinal inflammation. Representative diseases include neovascular age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion.

This invention belongs to the field of biotechnology and discloses the application of S100A9 inhibitors in the preparation of drugs for treating acute ocular hypertension-induced retinal injury. The study showed that the inflammation scores of AH patients in I / R model mice with APACG were significantly elevated, indicating a marked activation of inflammatory pathways. By comparing differentially expressed mediators, the pro-inflammatory alarmist S100A9 was screened. In vivo experiments confirmed that injection of the S100A9-targeting inhibitor Paquinimod significantly reduced ocular hypertension-induced retinal inflammation, decreased RGC death, and protected retinal structure and function. In vitro experiments confirmed that inhibiting S100A9 expression reduced the levels of inflammatory cytokines in microglia undergoing OGD / R. Furthermore, scRNA-seq analysis confirmed that inhibiting S100A9 upregulated Trem2 expression, thereby providing protection against high IOP-induced retinal injury, suggesting that the S100A9 / TREM2 signaling axis plays a crucial endogenous regulatory role in acute glaucoma-induced retinal neuroinflammation. Inhibition of this signaling axis can produce a neuroprotective effect by inhibiting the excessive activation of retinal microglia.

Applicant provides a method for treating or preventing a TMEM216-related disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a gene that supports or restores functional TMEM216 in the patient, such as for example retinitis pigmentosa (RP) or Joubert syndrome 2. The subject to be treated can be identified as harboring a mutation in the 5'UTR of GRCh38: chrll:g.61392563G. Also provided are vectors comprising the gene that supports or restores functional TMEM 216 in the subject. Diagnostic tests to identify these subjects also are provided herein.

Described herein are methods and devices for the long term treatment of ophthalmic disorders. Also disclosed are encapsulated cell therapy (ECT) devices that secrete a biologically active molecule and methods for using the same for the treatment of various kinds of ophthalmic disorders, including retinitis pigmentosa, geographic atrophy (dry age-related macular degeneration), glaucoma and / or macular telangiectasia.

The invention provides application of an itaconic acid compound in preparation of a medicine for treating retinal artery occlusion, and belongs to the technical field of treatment of fundus diseases. In particular to new application of itaconic acid and derivatives thereof in preparation of drugs for treating or preventing retinal artery occlusion, the technical cognition of itaconic acid compounds in the traditional application field is broken through, a new small molecule candidate drug is provided for prevention and treatment of retinal ischemic diseases, and the application value is definite. The damage to the structure of the retina in retinal artery occlusion can be relieved, and the visual function is effectively improved; the retina microglial cells can be promoted to be polarized to M2 type, the generation of anti-inflammatory factors IL-10 and TGF beta can be increased, and a protective effect is achieved in the inflammatory response of the retina; the effect of protecting retinal ganglion cells from apoptosis is also achieved. The compound can be used for related diseases such as retinal ischemic diseases, fundus retina inflammation injury and optic nerve injury, and has a wide application prospect for fundus diseases.

The present disclosure provides a method of treating retinitis pigmentosa type 11 (RP11) comprising administering to the eye of a subject a conjugate comprising a cell penetrating peptide (CPP) and an antisense oligonucleotide that modifies pre-mRNA splicing in the CNOT3 gene transcript and / or increases expression of a PRPF31 protein. Also disclosed are related pharmaceutical compositions and formulations thereof.